We are live on ! Find out more
SGH

Sivik Global Healthcare Portfolio holdings

AUM $132M
1-Year Est. Return 24.1%
This Fund
S&P 500
This Quarter Est. Return
-11.89%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$206M
AUM Growth
-$82M
Cap. Flow
-$47.7M
Cap. Flow %
-23.12%
Top 10 Hldgs %
36.68%
Holding
74
New
5
Increased
16
Reduced
28
Closed
17

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$6.31M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.37M
3
LLY icon
Eli Lilly
LLY
+$5.07M
4
HNT
HEALTH NET INC
HNT
+$4.68M
5
MCK icon
McKesson
MCK
+$4.08M

Sector Composition

Rank Sector Weight
1 Healthcare 83.73%
2 Financials 4.25%
3 Energy 1.47%
4 Industrials 1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CI icon
1
Cigna
CI
$72.3B
$10.1M 4.91%
75,000
+15,000
+25% +$2.18M
HNT
2
DELISTED
HEALTH NET INC
HNT
$9.63M 4.67%
160,000
+70,600
+79% +$4.68M
HUM icon
3
Humana
HUM
$43.6B
$8.95M 4.34%
50,000
-19,700
-28% -$3.64M
AET
4
DELISTED
Aetna Inc
AET
$8.75M 4.25%
80,000
+10,300
+15% +$1.19M
MCK icon
5
McKesson
MCK
$97.2B
$8.33M 4.04%
45,000
+19,273
+75% +$4.08M
HCA icon
6
HCA Healthcare
HCA
$86B
$6.58M 3.19%
85,000
-34,300
-29% -$3.04M
WCG
7
DELISTED
Wellcare Health Plans, Inc.
WCG
$6.46M 3.13%
75,000
-30,000
-29% -$2.63M
BIIB icon
8
Biogen
BIIB
$30.5B
$5.84M 2.83%
20,000
-4,800
-19% -$1.59M
AMGN icon
9
Amgen
AMGN
$208B
$5.53M 2.68%
+40,000
New +$6.31M
AGN
10
DELISTED
Allergan plc
AGN
$5.44M 2.64%
20,000
+100
+0.5% +$30.7K
CELG
11
DELISTED
Celgene Corp
CELG
$5.41M 2.62%
50,000
+10,300
+26% +$1.28M
GILD icon
12
Gilead Sciences
GILD
$163B
$5.4M 2.62%
55,000
+15,500
+39% +$1.72M
CVS icon
13
CVS Health
CVS
$133B
$5.31M 2.57%
55,000
-5,000
-8% -$526K
UHS icon
14
Universal Health Services
UHS
$9.93B
$5.27M 2.56%
42,222
-17,478
-29% -$2.43M
CYH icon
15
Community Health Systems
CYH
$405M
$5.2M 2.52%
147,213
-93,698
-39% -$4.3M
LLY icon
16
Eli Lilly
LLY
$1T
$5.02M 2.44%
+60,000
New +$5.07M
REGN icon
17
Regeneron Pharmaceuticals
REGN
$78.1B
$4.65M 2.26%
+10,000
New +$5.37M
RAD
18
DELISTED
Rite Aid Corporation
RAD
$4.55M 2.21%
37,500
+245
+0.7% +$40.8K
TEVA icon
19
Teva Pharmaceuticals
TEVA
$40B
$4.48M 2.17%
79,400
-10,000
-11% -$648K
BMY icon
20
Bristol-Myers Squibb
BMY
$132B
$4.44M 2.15%
75,000
+5,500
+8% +$349K
VRTX icon
21
Vertex Pharmaceuticals
VRTX
$121B
$4.17M 2.02%
40,000
+23,000
+135% +$2.95M
ALXN
22
DELISTED
Alexion Pharmaceuticals
ALXN
$3.91M 1.9%
25,000
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$11.7B
$3.69M 1.79%
35,000
+10,000
+40% +$1.34M
WBA
24
DELISTED
Walgreens Boots Alliance
WBA
$3.32M 1.61%
40,000
-19,600
-33% -$1.77M
LHCG
25
DELISTED
LHC Group LLC
LHCG
$3.03M 1.47%
67,705
-12,295
-15% -$540K

Similar funds

Sivik Global Healthcare's Q3 2015 Portfolio in Review

As of Q3 2015, Sivik Global Healthcare held 74 positions worth $206M, down 28% from $288M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sivik Global Healthcare withdrew a net $47.7M in Q3 2015, closing 17 positions and reducing 28 holdings. Its most notable exit was St Jude Medical, an estimated $6.58M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 84% a quarter earlier, followed by Financials and Energy.

Against the trend, Sivik Global Healthcare opened a new position in Amgen worth $5.53M.

  • Sivik Global Healthcare's largest Q3 2015 buy was Amgen: 40,000 shares worth $5.53M.
  • Sivik Global Healthcare added most to HEALTH NET INC in Q3 2015, an estimated $4.68M increase.
  • Sivik Global Healthcare's biggest Q3 2015 reduction was Tenet Healthcare, cutting an estimated $6.54M.
  • Sivik Global Healthcare fully exited St Jude Medical in Q3 2015, selling an estimated $6.58M.
  • Sivik Global Healthcare's ten largest holdings make up 37% of its $206M portfolio in Q3 2015.
  • Sivik Global Healthcare opened 5 new positions and closed 17 in Q3 2015.
  • Sivik Global Healthcare's portfolio value fell 28% quarter-over-quarter to $206M.

Based on Sivik Global Healthcare's 13F filing for Q3 2015, filed 4 Nov 2015.